Position in TNXP
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$6,444,789
+$6,444,789 QoQ
Shares Held
468,712
Ownership
2.94%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in TNXP Over Time
Shares Held
Position Value (USD)
Derivatives in TNXP
reported options exposure · as of Mar 31, 2026CallValue
$353,375
CallShares
25,700
PutValue
$239,250
PutShares
17,400
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026CITADEL ADVISORS LLC holds $5,784,241,435 across 374 Biotechnology names. TNXP ranks #113 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INSM |
INSMED Inc
|
2,182,571 | $356,894,009 | |
| 2 | ONC |
BeOne Medicines Ltd.
|
1,032,298 | $306,561,536 | |
| 3 | BMRN |
Biomarin Pharmaceutical Inc
|
4,512,634 | $254,918,694 | |
| 4 | JAZZ |
Jazz Pharmaceuticals plc
|
1,259,444 | $238,097,887 | |
| 5 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
453,843 | $237,573,195 | |
| 6 | BBIO |
BridgeBio Pharma, Inc.
|
3,173,940 | $235,696,783 | |
| 7 | TERN |
Terns Pharmaceuticals, Inc.
|
3,218,810 | $169,695,662 | |
| 8 | PTGX |
Protagonist Therapeutics, Inc
|
1,551,900 | $163,570,260 |
All Filings in TNXP
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $239,250 | 17,400 | Put | Defined | 2026-05-15 | |
| 2026-03-31 | $6,444,789 | 468,712 | Shares | Defined | 2026-05-15 | |
| 2026-03-31 | $353,375 | 25,700 | Call | Defined | 2026-05-15 | |
| 2025-12-31 | $621,676 | 39,800 | Put | Defined | 2026-02-17 | |
| 2025-06-30 | $254,630 | 7,077 | Shares | Defined | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||